Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Donepezil, rivastigmine, and vitamin E in Alzheimer disease: A combined P300 event-related potentials/neuropsychologic evaluation over 6 months
Autore:
Thomas, A; Iacono, D; Bonanni, L; DAndreamatteo, G; Onofrj, M;
Indirizzi:
Univ G D Annunzio, Inst Neurophysiopathol, Dept Oncol & Neurosci, Pescara,Italy Univ G D Annunzio Pescara Italy l, Dept Oncol & Neurosci, Pescara,Italy
Titolo Testata:
CLINICAL NEUROPHARMACOLOGY
fascicolo: 1, volume: 24, anno: 2001,
pagine: 31 - 42
SICI:
0362-5664(200101/02)24:1<31:DRAVEI>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
RANDOMIZED CONTROLLED TRIAL; PLACEBO-CONTROLLED TRIAL; CHOLINESTERASE-INHIBITORS; CLINICAL UTILITY; POTENTIALS P3; RATING-SCALE; DOUBLE-BLIND; DEMENTIA; ACETYLCHOLINESTERASE; MULTICENTER;
Keywords:
Alzheimer's disease; event-related potential; donepezil; vitamin E; rivastigmine;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
42
Recensione:
Indirizzi per estratti:
Indirizzo: Onofrj, M Serv Neurofisiopatol, Dept Oncol & Neurosci, Via Fonte Romana, I-65100 Pescara, Italy Serv Neurofisiopatol Via Fonte Romana Pescara Italy I-65100 aly
Citazione:
A. Thomas et al., "Donepezil, rivastigmine, and vitamin E in Alzheimer disease: A combined P300 event-related potentials/neuropsychologic evaluation over 6 months", CLIN NEUROP, 24(1), 2001, pp. 31-42

Abstract

The latency of P300 "cognitive" event-related potentials changes if cholinergic activities of the central nervous system are pharmacologically manipulated. We tested the hypothesis that the new cholinesterase inhibitors donepezil (DPZ) and rivastigmine (Riv) may have an effect on the frequently abnormal P300 component in patients with Alzheimer disease (AD), thereby allowing a significant evaluation of cholinesterase inhibitors. We evaluated 60 patients with mild to moderately severe probable AD, ill comparison with 60age-matched control subjects, with P300 recordings and neuropsychologic examinations. Forty patients were randomly assigned in a double-blinded trialto 5-10 mg/d DPZ versus 2,000 IU/d vitamin E, and 20 patients were insteadtreated in an open trial with 1.5 to 12 mg/d Riv. In patients treated withvitamin E, we observed latency increments (7.4 +/- 3.5 msec) correlated with worsening neuropsychologic test scores. In patients treated with DPZ acid Riv, we found significant P300 latency reductions (15.3 +/- 3.2 msec and 22.0 +/- 3.3 msec). Shorter P300 latencies were associated with higher Wechsler Adult Intelligence Scale scores and with lower AD Assessment Scale-cognitive subscale (ADAS-cog) scores (R = 0.72). Correlations between ADAS-cogchanges and P300 changes significantly separated patients treated with DPZand Riv from those treated with vitamin E. Administration of DPZ and Riv reduced the latencies of P300 components proportionately to neuropsychologictest improvements. Combined P300 and neuropsychologic test evaluation significantly separated DPZ-treated patients and Riv-treated patients from vitamin E-treated patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 08:40:02